Compare Abeona Therapeutics Inc (ABEO) vs Axogen Inc (AXGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Axogen Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Axogen Inc trades at $43.17 (market cap $2.37B). The key difference: Axogen Inc is far larger — about 6.3× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | AXGN | |
|---|---|---|
Market Cap | $373.32M | $2.37B |
Sector | Health | Technology |
52-Week High | $7.23 | $46.19 |
52-Week Low | $4.17 | $11.28 |
Enterprise Value | $228.22M | $2.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AXGN trades at $45.97, up 0.17% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 earnings of $0.07 per share, missing estimates, yet maintains a strong gross margin of 75.01%. Recent news highlights a bullish rebound and raised 2026 guidance, with 84% of analysts rating it a Buy. Support is at $44, with resistance at $47.
Outlook is cautiously optimistic due to strong analyst support and recent institutional interest, but risks include consecutive earnings misses and negative net income margins. The consensus price target of $47.60 suggests modest upside, though execution on guidance and reimbursement wins are critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
